These structural motifs can be found in the MC4R antagonist PF-07258669 in phase 1 clinical trials from Pifzer and in the development of the FGFR4 selective inhibitor Roblitinib from Novartis.
There are at least 100 that can affect weight, including one called MC4R. It is thought about one in every 1,000 people carries a defective version of the MC4R gene, which works in the brain to ...